Summary •Shares Battered After Failure to Show Efficacy in Ulcerative Colitis (UC) Phase II. •CEO Van Bokkelen Answers the Tough Questions Including: Why No Recent Insider Buying?. •The Science Behind Multistem Stroke Therapy. •Efficacy in Stroke Trial Unleashes Tremendous Value.